Plexpress and SBW Partner to Offer TRAC Gene Expression Analysis

May 9, 2012 - PRLog -- Plexpress, developer of the innovative TRAC platform for high-throughput gene expression analysis, has announced it will partner with SBW to provide SBW’s customers with access to Plexpress’ novel technology. SBW, a contract research organisation serving the drug discovery market, will offer Plexpress’ pre-validated TRAC Cytochrome P450 (CYP) family multiplex assays as part of its portfolio for investigating in vitro drug interactions and pre-clinical ADME-Tox profiles. Such a service is expected to be very popular, especially given a recent draft report from the FDA, which suggests that drug discovery researchers use CYP mRNA induction, rather than CYP activity, to assess drug metabolism and activity (1).

TRAC (Transcript Analysis with the aid of Affinity Capture) technology is a new approach to measuring gene expression changes that offers several benefits over qPCR and microarrays, including higher sample throughput and increased assay speed, while simultaneously reducing technical variation. For more information about how TRAC could boost the efficiency of your drug discovery pipeline, please visit www.plexpress.com. For more information about the new SBW service utilising TRAC, view the full release by visiting the SBW website or contact SBW directly at info@sbw.fi.

Reference:

1. FDA Guidance for Industry Report (Feb 2012): Drug Interaction Studies Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations